Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Hydroxyurea
Drug ID BADD_D01110
Description An antineoplastic agent that inhibits DNA synthesis through the inhibition of ribonucleoside diphosphate reductase.
Indications and Usage For management of melanoma, resistant chronic myelocytic leukemia, and recurrent, metastatic, or inoperable carcinoma of the ovary and Sickle-cell anemia.
Marketing Status approved
ATC Code L01XX05
DrugBank ID DB01005
KEGG ID D00341
MeSH ID D006918
PubChem ID 3657
TTD Drug ID D07CWD
NDC Product Code 0904-6939; 35369-0006; 49452-3650; 55154-7143; 61269-403; 68084-284; 70518-3615; 51927-0072; 0555-0882; 55154-3554; 69315-164; 38779-1354; 42291-321; 71770-105; 49884-724; 17337-0023; 0003-6335; 0003-6337; 60429-265; 61269-835; 70518-0916; 55512-0003; 61269-402; 71770-120; 0003-0830; 51552-0851; 62049-135; 0003-6336; 61269-404; 10135-702; 71052-323; 17337-0022
UNII X6Q56QN5QC
Synonyms Hydroxyurea | Hydroxycarbamid | Oncocarbide | Hydrea
Chemical Information
Molecular Formula CH4N2O2
CAS Registry Number 127-07-1
SMILES C(=O)(N)NO
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Metastatic neoplasm16.16.01.007--Not Available
Poisoning12.03.01.004--Not Available
White blood cell disorder01.02.05.0020.000168%Not Available
Decreased appetite08.01.09.028; 14.03.01.0050.001276%
Gastrointestinal ulcer07.04.04.002--Not Available
Ill-defined disorder08.01.03.049--Not Available
Blood disorder01.05.01.004--Not Available
Drug intolerance08.06.01.0130.001321%Not Available
Hepatobiliary disease09.01.08.003--Not Available
Immunosuppression10.03.02.0010.000246%Not Available
Renal impairment20.01.03.0100.001567%Not Available
Haemorrhagic diathesis24.07.01.020; 01.01.03.0030.000168%Not Available
Neutropenic colitis07.08.01.014; 01.02.03.0100.000112%Not Available
Radiation skin injury23.03.11.007; 12.05.02.004--
Hypophagia19.09.01.004; 14.03.01.006; 07.01.06.0100.000224%Not Available
Skin haemorrhage24.07.01.103; 23.06.07.0010.000224%Not Available
Osteonecrosis of jaw24.04.05.005; 15.02.04.0100.000112%
Chronic kidney disease20.01.03.0170.000336%
Pulmonary arterial hypertension24.08.03.003; 22.06.01.0020.000224%Not Available
Bone marrow failure01.03.03.0050.000895%
Cytopenia01.03.03.0120.000168%Not Available
Low birth weight baby18.04.02.0030.000168%Not Available
Nail atrophy23.02.05.010--Not Available
Tongue pigmentation07.14.02.0170.000246%Not Available
Acute kidney injury20.01.03.016--
Foetal growth restriction18.03.01.0020.000224%
Leukostasis syndrome22.01.03.008; 17.02.10.018; 16.32.03.018; 01.02.01.0110.000112%Not Available
Multiple organ dysfunction syndrome08.01.03.0570.000168%
Myeloproliferative neoplasm16.21.03.006; 01.13.03.0060.000280%Not Available
Angiosarcoma24.03.06.003; 16.16.03.0010.000112%Not Available
The 11th Page    First    Pre   11 12 13    Next   Last    Total 13 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene